BusinessImmune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.By Nasdaq OMXAug 23, 2017, 1:04 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:34 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
